These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 24750545

  • 1. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y.
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [Abstract] [Full Text] [Related]

  • 2. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P.
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
    Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
    [Abstract] [Full Text] [Related]

  • 4. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
    Wu R, Chi X, Wang X, Sun H, Lv J, Gao X, Yu G, Kong F, Xu H, Hua R, Jiang J, Sun B, Zhong J, Pan Y, Niu J.
    Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
    [Abstract] [Full Text] [Related]

  • 5. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
    Fernández-Carrillo C, Coto-Llerena M, González P, Crespo G, Mensa L, Caro-Pérez N, Gambato M, Navasa M, Forns X, Pérez-del-Pulgar S.
    J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
    Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K, Hiroshima Liver Study Group.
    J Gastroenterol; 2014 Dec; 49(12):1548-56. PubMed ID: 24362944
    [Abstract] [Full Text] [Related]

  • 8. Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis.
    Li Y, Yang L, Sha K, Liu T, Zhang L.
    Int J Infect Dis; 2016 Dec; 53():52-58. PubMed ID: 27810523
    [Abstract] [Full Text] [Related]

  • 9. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S, Thong VD, Payungporn S, Poovorawan K, Prapunwattana P, Poovorawan Y, Tangkijvanich P.
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [Abstract] [Full Text] [Related]

  • 10. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA, Congiu M, Bonanzinga S, Sandhu MK, Kia YH, Bell SJ, Nguyen T, Iser DM, Visvanathan K, Sievert W, Bowden DS, Desmond PV, Thompson AJ.
    Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
    [Abstract] [Full Text] [Related]

  • 11. Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance.
    Palmieri O, Ippolito AM, Margaglione M, Valvano MR, Gioffreda D, Fasano M, D'Andrea G, Corritore G, Milella M, Andriulli N, Morisco F, Giannitrapani L, Latiano A, Fontana R, Gatti P, Tundo P, Barone M, Cozzolongo R, Santantonio T, Andriulli A.
    Liver Int; 2014 Oct; 34(9):1369-77. PubMed ID: 25283962
    [Abstract] [Full Text] [Related]

  • 12. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
    Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA.
    AIDS; 2014 Jan 02; 28(1):133-6. PubMed ID: 24072198
    [Abstract] [Full Text] [Related]

  • 13. Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.
    Nozawa Y, Umemura T, Katsuyama Y, Shibata S, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Yoshizawa K, Ota M, Tanaka E.
    Tissue Antigens; 2014 Jan 02; 83(1):45-8. PubMed ID: 24355007
    [Abstract] [Full Text] [Related]

  • 14. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, Izumi N, Tohda S, Watanabe M.
    J Med Virol; 2017 Jul 02; 89(7):1241-1247. PubMed ID: 28036111
    [Abstract] [Full Text] [Related]

  • 15. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M.
    PLoS One; 2015 Jul 02; 10(12):e0145622. PubMed ID: 26699619
    [Abstract] [Full Text] [Related]

  • 16. Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.
    Morales-Vásquez L, Miranda-Avalo EI, Rodríguez-Medina JR, Quiñones-Badillo Y, Marqués-Lespier J, Muñoz-Acabá J, Pastrana R, Pérez-Cardona CM, Yamamura Y, Torres EA.
    P R Health Sci J; 2014 Dec 02; 33(4):177-83. PubMed ID: 25563035
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.
    Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A.
    Mol Med Rep; 2012 Feb 02; 5(2):525-8. PubMed ID: 22052088
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
    Krämer B, Nischalke HD, Boesecke C, Ingiliz P, Voigt E, Mauss S, Stellbrink HJ, Baumgarten A, Rockstroh JK, Spengler U, Nattermann J.
    AIDS; 2013 Nov 13; 27(17):2817-9. PubMed ID: 23939236
    [Abstract] [Full Text] [Related]

  • 20. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
    Xie X, Zhang L, Chen YZ.
    Hum Immunol; 2016 Jul 13; 77(7):609-15. PubMed ID: 27180197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.